Dr. He on the Future of Durvalumab Plus Chemotherapy in Biliary Tract Cancer

Video

Aiwu Ruth He, MD, PhD, discusses next steps for durvalumab in combination with gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Aiwu Ruth He, MD, PhD, scientific lead, Liver & Biliary Cancers, MedStar Georgetown University Hospital, discusses next steps for durvalumab (Imfinzi) in combination with gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

The phase 3 TOPAZ-1 study (NCT03875235) evaluated first-line durvalumab, an immunotherapy, in combination with the chemotherapy regimen gemcitabine plus cisplatin in this patient population. The addition of durvalumab resulted in an 18-month overall survival (OS) rate of 35.1% compared with 25.6% with placebo plus chemotherapy. This benefit was seen regardless of primary tumor location. Additionally, the combination demonstrated a manageable safety profile, with grade 3 or 4 treatment-related adverse effects occurring in 62.7% of patients who received durvalumab vs 64.9% of patients who received placebo.

TOPAZ-1 is the first phase 3 trial to show that adding immunotherapy to chemotherapy improves OS in this population, He explains. Going forward, further investigation with immune checkpoint inhibitors in cholangiocarcinoma may evaluate dual immunotherapy and immunotherapy plus targeted therapy and chemotherapy, He notes.

The immunotherapy and chemotherapy combination was also well tolerated in TOPAZ-1, as durvalumab did not lead to a significant increase in toxicity, He explains. This regimen could be built upon with additional immunotherapy combinations to improve patient outcomes and quality of life, He concludes.

Related Videos
Jeffrey Zonder, MD
Jun Gong, MD
John Michael Bryant, MD,
Chandler H. Park, MD, FACP
Kathryn Beckermann, MD, PhD
Eleonora Dondossola, PhD
William B. Pearse, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; director, Yale SPORE in Skin Cancer; vice chair, Translational Research, Internal Medicine; chief, Division of Skin and Kidney Cancer; associate cancer center director, Education, Training and Faculty Development; deputy section chief, Medical Oncology, Yale Cancer Center